Recent Updates in Pharmacological Properties of Chitooligosaccharides

Marmouzi, Ilias; Ezzat, Shahira M.; Salama, Maha M.; Merghany, Rana M.; Attar, Aisha M.; EL-Desoky, Ahmed M.; Mohamed, Shanaz O.

doi:https://doi.org/10.1155/2019/4568039

BioMed Research International

On this page

Abstract Introduction Results and Discussion Conflicts of Interest Acknowledgments References Copyright Related Articles

Review Article | Open Access

Volume 2019 | Article ID 4568039 | https://doi.org/10.1155/2019/4568039

Recent Updates in Pharmacological Properties of Chitooligosaccharides

Ilias Marmouzi,¹Shahira M. Ezzat,^2,3Maha M. Salama,^2,4Rana M. Merghany,⁵Aisha M. Attar,⁶Ahmed M. EL-Desoky,⁷and Shanaz O. Mohamed⁸

Academic Editor: Isabelle Chevalot

Received09 Mar 2019

Revised26 Jun 2019

Accepted05 Aug 2019

Published31 Oct 2019

Abstract

Chemical structures derived from marine foods are highly diverse and pharmacologically promising. In particular, chitooligosaccharides (COS) present a safe pharmacokinetic profile and a great source of new bioactive polymers. This review describes the antioxidant, anti-inflammatory, and antidiabetic properties of COS from recent publications. Thus, COS constitute an effective agent against oxidative stress, cellular damage, and inflammatory pathogenesis. The mechanisms of action and targeted therapeutic pathways of COS are summarized and discussed. COS may act as antioxidants via their radical scavenging activity and by decreasing oxidative stress markers. The mechanism of COS antidiabetic effect is characterized by an acceleration of pancreatic islets proliferation, an increase in insulin secretion and sensitivity, a reduction of postprandial glucose, and an improvement of glucose uptake. COS upregulate the GLUT2 and inhibit digestive enzyme and glucose transporters. Furthermore, they resulted in reduction of gluconeogenesis and promotion of glucose conversion. On the other hand, the COS decrease inflammatory mediators, suppress the activation of NF-κB, increase the phosphorylation of kinase, and stimulate the proliferation of lymphocytes. Overall, this review brings evidence from experimental data about protective effect of COS.

1. Introduction

Marine sources constitute nearly the half of the nature biodiversity and are considered the largest remaining reservoir of natural structures of food functional interest. Among marine food molecules, chitooligosaccharides (COS) are derivatives of chitosan with a lower molecular weight (MWt) [1]. The bioactivity and physicochemical properties of COS is highly dependent on their chemical characteristics. COS are produced by degradation of either chitin or chitosan via physical hydrolysis, acid hydrolysis, and enzymatic hydrolysis [2]. These oligomers usually present a degree of polymerization (DP) of <50–55 and a molecular weight (MWt) of <10,000 Da [3], and also they are characterized by a degree of deacetylation (DD), which is related to GlcN molar fraction in the compound, MWt distribution (polydispersity), and N-acetylation pattern (PA) [4]. In contrast with chitosan, the COS have higher solubility in water and their viscosity is low, so they are partially soluble in dimethyl sulfoxide and methanol but insoluble in ethanol and acetone [3]. COS have been traditionally obtained by chemical digestion with strong acids. However, many difficulties are associated with the traditional processes. In this regard, the use of chemical, enzymatic, or microbial hydrolysis is commonly employed for COS production. Degradation of chitosan using enzymatic hydrolysis has more benefits than using chemical hydrolysis regarding controllability and predictability [5–7]. Chitosan may be particularly degraded by chitinases, chitosanases, and lysozymes [3]. Even though chitinases and chitosanases obtained from microbes produce a relatively higher proportion of COS, their usage is limited due to their elevated price. So, many nonspecific enzymes are used, including cellulases, pectinases, lipases, amylases, and deacetylases [2, 8]. Moreover, COS having certain PA pattern may be generated by bacterial deacetylases [9]. COS generated by these enzymes are mainly consisted of a combination of oligomers with different PA, DD, and DP. Recently, COS have received much attention in biomedical and food industries mainly because of their solubility, biocompatibility, biodegradability, and nontoxicity. COS had broad range of applications and proved diverse promising biological activities, and subsequently, they drew attention in drug therapy [6,10]. This review focuses on marine COS as a therapeutic strategy against diabetes, oxidative stress, and inflammation. The pharmacokinetic profile and the molecular and biochemical regulatory pathways of these molecules are discussed with updated bibliographic data.

2. Search Methodology

Electronic searches were performed in PubMed, Scopus, Google Scholar, and Web of Science databases, using the following keywords: chitooligosaccharides, chitosan-oligomers, and chitooligomers, to identify relevant articles. All published articles were evaluated, and a total of 103 papers of important contribution were selected to compose the present review.

3. Results and Discussion

3.1. COS Antioxidant Properties

COS exhibit antioxidant properties in vitro and in vivo; the literature data reporting antioxidant COS are summarized in Tables 1 and 2. COS exhibited strong scavenging activity on the HO^• and O₂^• radicals [11]; however, their activity is relatively weak on alkyl and DPPH radicals. In this work, the activity was related to the concentration, MWt, and tested radicals. Haung et al. [12] modified COS into two derivatives by introducing carboxyl and quaternary amino groups to their amino positions with varying substitution levels. The aim of this modification was to change the ability of hydrogen atoms’ whole quantity to react with free radicals and make them more capable to chelate ion metals. COS were also previously prepared from different molecular weights using incomplete chitosan hydrolysis, and their free radical scavenging activity was estimated and correlated to their MWt and compared to aminoglucose [13]. The antioxidant action of COS, vitamin C, and aminoglucose was dose-dependent in a phenazine methosulfate-β-nicotinamide adenine dinucleotide system, though it was nonlinear. Yang et al. [13] suggested that COS amino groups may have an efficient task in their antioxidant action due to their short chains, regarding chitosan which forms well-built intramolecular and intermolecular bonds and reduces the reaction of the free radicals with the amino and hydroxyl groups of the polymers. Further investigation of COS with different MWt (<1000 Da) on intracellular radical (H₂O₂, ^•OH, and ROO^•) using B16F1 and murine melanoma cell line [14] demonstrated marked decrease in those radical species supporting the concept that a lower MWt is essential for the radical scavenging activity in biological systems. Also, COS low MWt suppressed NF-κB gene promoter activity, proving their ability to avoid diseases associated with oxidative stress. Lee et al. [15] evaluated the protective effects of sulfated chitosan and COS by employing a fluorescence-activated cell sorter (FACS) on hydrogen peroxide and plasmid DNA strand breaks assay. The sulfated chitosan and sulfated COS (S-COS), having highest alkyl radical scavenging activity, were selected to investigate their protective liver cell effect against H₂O₂. Results proved that the S-COS III showed the highest protective activities on liver cells and exhibited a protective effect on H₂O₂-induced DNA damage. Fernandes et al. [16] studied the free radical scavenging action of two COS combinations and a low MWt LM-chitosan against two biological molecules, phages and erythrocytes, that underwent different oxidative stress situations. The potential inhibition of COS for each tested concentration was higher than that of LM-chitosan. Higher concentrations of COS potentiated the H₂O₂ action; in contrast, LM-chitosan potentiated H₂O₂ effect, at lower concentrations. In addition to the previous mechanisms, either COS or LM-chitosan had the capability to keep RBCs from oxidation of Hb by AAPH at conc. of 0.05–0.005 mg/mL. Fernandes et al. [16] concluded that COS may be utilized as antioxidants in vivo, at concentrations moderately low to stop more oxidative injury to cells, though this was not in agreement with chemical methodology. Ngo et al. [17] studied the effect of gallic acid conjugated to COS (gallate-COS) on cellular antioxidant activity. The mechanism of the antioxidant activity of gallate-COS was assessed by measuring the levels of gene expression of GSH and SOD antioxidant enzymes. Analysis of the results showed that gallate-COS reduced free radical-catalyzed activation of NF-κB protein (this is a transcription factor-mediated expression of several genes in osteoarthritis condition). Accordingly, gallate-COS may be utilized as a potent antioxidant to protect bone cells from oxidative stress. Lu et al. [18] investigated the antioxidative role of S-COS opposing H₂O₂-mediated injury in pancreatic MIN6 β-cell line. Results revealed that S-COS were safe at conc. of 0.1 to 0.5 mg/mL. Moreover, S-COS can augment the viability of cells, decreasing ROS generation and decreasing the LDH and MDA in oxidative damaged β-cells demonstrating its antioxidant effect. The suggested mechanisms are due to the S-COS improvement of activity of antioxidant enzymes, reduction of ROS generation, and inhibition of MIN6 β-cell apoptosis. Likewise, increasing the DS has an impact on the defense mechanisms against oxidative damage. Many studies estimated the different antioxidant action of LM-polysaccharides (LMPS) prepared by starch (LMST), agar (LMAG), and chitosan (LMCH), on fibroblasts of skin and correlated the activity regarding their amine, hydroxyl, and sulphur groups. The studies reported that the variation in antioxidant activity of LMPS might be because of LMPS functional groups, ability to chelate metal ions, ability to transfer electrons, and capacity to stabilize radicals. This high capacity to stabilize radicals and metal ion chelating property of LMCH resulted in a potent antioxidant action that is advanced to that of LMAG. So, LMCH showed a high ability to reduce ROS generation, reduced lipid peroxidation of the cells, and inhibited DNA damage due to oxidative stress. Accordingly, they reported that LMCH may have an efficient role in treating skin complications and can be used as sun protective agents [19]. Other reports indicated that low MW COS exhibited the highest antioxidant activities [20].

Recently, Qu and Han [39] investigated COS antioxidant action in vivo using high-fat diet (HFD) mice model. Mice groups were administered normal diet, HFD, or HFD + COS (0.5%) for a period of 6 weeks. Group fed with HFD +0.5% COS significantly restored the action of GPx, CAT, and SOD in liver, stomach, and blood when comparing it with the HFD-administered group. Morphologically, there was a significant decrease in the measured parameters: decreased villus height compared with the group fed with HFD. However, those fed with HFD + COS (0.5%) were the same in the height of villus compared with the control. This result supports the improvement in intestinal integrity when COS was added to their diet. Furthermore, results showed that gallate-COS had a defensive potential regarding H₂O₂-mediated DNA oxidative harm [21]. Gallate-COS reduced the generation of reactive oxygen species inside H₂O₂-mediated A549 cells. On the other hand, Xie et al. [40] proved that supplementary maternal diet with COS enhanced blood SOD level, which resulted in decreasing MDA content. Also, expression of some antioxidative genes mRNA was enhanced in the mothers’ placenta. Jiang et al. [41] also reported the N-acetyl chitooligosaccharides can attenuate amyloid β-induced damage by reducing the oxidative stress in animal and cell models of Alzheimer’s disease.

3.2. COS Anti-Inflammatory Effect

COS are promising anti-inflammatory agents (Table 3). LM-COS comprising of glucosamine (GlcN) n, where n = 3–5, were fit for restraining both antigen-invigorated degranulation and cytokine production in rodent basophilic leukemia cells (RBL-2H3) [53]. Moreover, the defensive impact of LM-COS regarding ovalbumin-incited lung irritation in asthma mouse model (16 mg/kg/day) was also established [53]. Dung et al. [54] demonstrated that COS upregulated the declarations of CD86 and MHCII on SDCs and advanced the emission of TNF-α. Additionally, nonsoluble COS invigorated the differentiation of the CD4+T in dendritic cells. COS were examined for their consequences for epithelial cells as well as tissues [55]. Chitooligomers fundamentally invigorated the mitochondrial action of in vitro keratinocytes’ cultures. Supplementation with COS significantly reduces the intestinal provocative reaction, which is corresponding with the enactment of CaSR and the suppression of NF-κB signaling pathway under inflammatory conditions [54].

COS produce an anti-inflammatory impact via Nrf2/MAPK-stimulated HO-1 production [56]. Kim et al. [57] showed that LM-S-COS suppressed the generation of nitric oxide and some inflammatory mediators like TNF-α as well as IL-6 in LPS-induced RAW 264.7 cells. Kunanusornchai et al. [58] indicated that COS may have in vitro as well as in vivo synovial anti-inflammatory activity through AMPK phosphorylation. Moreover, COS showed suppressor action on LPS-stimulated reduction in the Bcl-2/Bax fraction and higher activity of caspase-3 and BKCa [42]. One of the techniques that COS can perform to suppress apoptosis of cells is by controlling BKCa channel. Then again, COS can hinder the activation of LPS-prompted p38 as well as quicken the activation of O-GlcNAc glycosyltransferase enzyme. Li et al. [59] found that five chitooligomers from dimer to hexamer (chitobiose, chitotriose, chitotetraose, chitopentaose, and chitohexaose) separated from COS enhanced NF-κB-related luciferase gene expression as well as inhibited NF-κB gene transcription. COS reduced OGT-related NF-κB O-GlcNAcylation and so inhibited LPS-mediated inflammation of the vascular endothelia [60]. Polar chitosan formulation based on nanoparticles CMC-COS NP and SC-COS NP was produced by the development of complexes of polyelectrolyte [61]. Injection of CMC-COS NP and SC-COS NP changed Th cytokine content in blood and induced the differentiation of lymphocytes in spleen in vivo, approving their ability to control cell-induced immune reactions. COS efficiently suppressed TNF-α-mediated activation of ICAM-1 and VCAM-1 at transcription as well as translation levels [62]. Liu et al. [62] found that COS suppressed LPS-mediated IL-8 activation in HUVECs via blocking p38 MAPK as well as PI3K/Akt pathways. COS decreased the generation of proinflammatory mediators such as IL-1β and nitric oxide in LPS-mediated RAW 264.7 cells [63]. COS may also defend inflammation and oxidative stress in LPS-mediated complications in vivo, which may present valuable properties for septic patients [63]. Results showed that COS decreased the contents of nitric oxide and PGE2 generation by inhibiting COX-2 and iNOS activation without considerable cytotoxicity in BV-2 microglia [64]. Notably, COS exerted anti-inflammatory effect through blockade of IκB-a decomposition, NF-κB translocation, and MAPK phosphorylation (dose dependent). Xu et al. [65] demonstrated that COS suppressed EGF-mediated cell migration via blocking EGFR/MAPK pathway. COS suppressed the proliferation of epithelia cells of the breast via deactivation of GnT-V as well as its products [66]. Nutritional supplements containing COS or GMOS increased IL-1β gene activation of mucosa in jejuna as well as lymph nodes, when compared to lincomycin supplements [67]. Yoon et al. [68] showed that COS can act as an anti-inflammatory agent through stimulating TNF-α in LPS-mediated inflammatory complications of RAW 264.7 cells. COS may also be efficient in treating inflammatory bowel disease via inhibiting NF-κB pathway as well as apoptosis of cells of epithelia in intestine [69]. Zhang et al. [70] found that COS may possess potential stimulating incidence in the immune system by enhancing the production of TLR4 on macrophage while Zhang et al. [71] found that they efficiently suppresses the IL-1β-mediated chondrocytes’ apoptosis through activation of p38 MAPK pathway. Dai et al. reported protective effect of COS against neuroinflammation via its inhibitory effect on BACE1 [22]. Moreover, COS have been shown to exhibit immunostimulatory effect via the MAPK and PI3K/Akt signaling pathways [72]. Another study demonstrated that fully deacetylated and acetylated COS exhibit an ability to reduce the level of TNF-α in murine macrophages after LPS stimulation [73].

3.3. COS Antidiabetic Mechanisms

COS exert its antidiabetic activity through different mechanisms (Table 4). In a study made by Liu et al. [82], the highly deacetylated COS (90%) of molecular weight 1200 Da obtained by chitosan enzymatic degradation using chitosanase enzyme. COS incidence on pancreatic islet cell viability as well as β-cell line using MTT colorimetric test was established. The COS sufficient entrance into cells of pancreatic islet was approved by COS-induced insulin secretion assays through utilizing cultures of rat monolayer islet cells, where COS at a concentration (100 mg/L) enhanced the differentiation of islets and induced recovery of damaged pancreatic β-cells increasing insulin release to 14 days, when comparing the results to the group of normal control. COS also promoted β-cell proliferation in pancreas (INS-1) and upregulated GLUT2 mRNA gene expression, which could stimulate insulin release. COS also can defend INS-1 cell against apoptosis [83] which occurs as a result of increasing the circulating glucose, saturated FA [84, 85], inflammatory markers [86], and oxidative stress [87–89].

Streptozotocin (STZ) is a molecule that may act as selective cytotoxic agent for pancreatic cells as well as generating ROS that results in DNA degradation [90, 91]. COS showed a protective effect on INS-1 cell in opposition to apoptosis mediated by STZ, through raising the activity of reduced SOD and reduction of elevated levels of malondialdehyde (MDA) content in pancreas homogenate [82, 83, 92]. On the other hand, COS may not be able to defend INS-1 cell against harm mediated by some proinflammatory cytokines, such as IFN-γ, TNF-α, or IL-1β that can enhance β-cell apoptosis via the intrinsic mitochondrial apoptotic pathway [93].

In vivo experiments in STZ-induced diabetes mellitus (DM) in mice showed that COS could decrease 2 h plasma glucose in 60 days at a dose of 500 mg/kg, to 16.14 mmol/L, when comparing the results to the diseased DM group at . This study also proved that the dose 500 mg/kg of COS also showed the best incidence in the oral glucose tolerance test (OGTT) through improving the sensitivity to insulin. Area under the curve (AUC) for the DM group was regarded as 100%, and AUC of normal control group was only calculated as 17.69% of the DM group AUC, so treatment with 500 mg/kg of chitooligosaccharides caused a decrease to 68.69% of the DM group AUC [82]. STZ-mediated type 2 DM results in insulin resistance as well as β-cell disordering [94]. In a study designed by Ju et al. [83], STZ-diabetic rats showed metabolic disorders including hyperglycemia, hyperlipidemia, insulin resistance, and ruptured islet. COS showed in vivo hypoglycemic effect at a dose of 1000 mg/kg, and it exerts its effect by reducing fasting serum glucose as well as insulin levels, increasing index of insulin sensitivity and improving OGT, protecting pancreatic islet, and reducing insulin resistance. COS also caused a considerable increase in glycogen level in liver, and this might be through increasing the transfer of blood glucose into liver glycogen by increasing glucokinase.

Chronic hyperglycemia may be acquired as a result of the failure of the body peripheral tissues to utilize glucose properly. GLUT-4 is a vital glucose transporter and regulator of its metabolism found in skeletal muscles and adipocytes [95, 96]. In this study, the expression of GLUT-4 was decreased in adipose and skeletal tissues in diabetic animal model. Treatment of the diabetic animals with COS caused a significant increase in GLUT-4; this effect may be attributed to COS which can upregulate GLUT-4 mRNA expression, thus improving insulin resistance. In vivo administration of COS in STZ-diabetic rats could also repair the injury of pancreatic tissues and restore the BWt ratio of pancreas. Liu et al. [82] suggested that COS being an alkaline help in decreasing the plasma glucose through increasing the pH of the body fluids and thus raise insulin sensitization. COS may also maintain normal metabolism of plasma glucose by regulating the endocrine system as well as reducing insulin secretion to standard levels. Administration of COS to alloxan-induced type II diabetes mellitus in mice at two doses 5 and 10 mg/kg decreased plasma glucose levels by 54.1% on day 21st of the experiment, significantly increased hepatic glycogen content, and gradually increased the body weight of the treated mice, while the diabetic mice continued to lose weight [97]. SGOT and SGPT activities were increased significantly in alloxan-induced diabetic mice [97]. This increased activity of transaminases occurs in the absence of insulin due to the increase of amino acids levels in the blood causing increased gluconeogenesis and ketogenesis [97]. SGOT and SGPT which act as indicators of liver function were come towards control level after treatment with COS (10 mg/kg); this indicates the normal liver function [97] COS (10 mg/kg) have also caused alteration in lipid metabolism and this was evidenced by decreasing the levels of serum LDL, VLDL, triglycerides, and total cholesterol levels which were elevated due to diabetes and increased HDL-c level [97]. Interestingly, these results from Ha et al. [98] study suggest that deep-sea water having COS showed a higher inducible result on glucose uptake more than either alone. Also, this consequence is accomplished by activating different signaling pathways associated with GSV trafficking. Yu et al. [99] showed that COS may have dual mechanism of actions as antidiabetic in intestinal cell lines, either through suppressing α-glucosidase and SGLT1 as well as GLUT2, or through improving adipocyte proliferation and activation of PPARγ as well as its targeted genes, like FABP4 and adiponectin, where these properties were enhanced through cotreating with BADGE (PPARγ antagonist). Also, COS considerably enhanced glucose uptake. In vivo COS administration did not demonstrate any antidiabetic/hypocholesterolemic effects, since glycemia and cholesterol levels in GK rats were not altered [100]. In a recent study [101], the consumption of COS with complexes to resistant starch produced a higher capability for insulin sensitivity revival. Gene expression of liver tissues obtained from COS-injected rats approved that this effect may be due to increase in the liver glucose alteration through activation of GS2 as well as GYG1, decrease in gluconeogenesis through activation of G6PC1, and change in glucolipid metabolism through activation of Insig-2. Also GlcNAc 2 decreased lipid peroxidation as well as inflammatory markers in pancreatic cells with enhancement of SOD activity and decreased IL-1b, NF-κB, MDA, and TNF-α contents [102]. GlcNAc 2 may also appreciably deactivate MAPK pathway particularly through IL-1b-Erk/p38-histone H3 pathway in type 2 DM in vivo.

4. Current Evidence and Perspectives

Marine compounds with interesting in vivo antioxidant properties are excellent drug candidates against inflammation, diabetes, and oxidative stress. COS especially show interesting properties in experimental data. COS are generated from chitin deacetylation and hydrolysis reactions, through enzymatic or chemical methods. The COS are normally absorbed via the epithelia of the intestine and mainly dispersed to the hepatocytes, splenocytes, and renal cells. COS are also decomposed by lysozymes before being excreted via urine. Due to their high polarity, low viscosity, safety, and good pharmacokinetic profile, COS have already been integrated in many functional formulations, such as COS capsules. It is noteworthy that, among the several publications that focuses on COS bioactivity, many recent works detailed the molecular mechanisms and targeted signaling pathways of COS action. However, many mechanisms are not evidenced, mainly because of poor reproducibility, divergence in physicochemical properties, and dose effect. Among the proposed mechanisms are, e.g., the pancreatic islet proliferation, the increase in insulin secretion and sensitivity, the reduced postprandial glucose and improved glucose uptake, the upregulatory GLUT2 expression and inhibition of digestive enzymes and glucose transporters, the reduction of gluconeogenesis and promotion of glucose conversion, the decrease in inflammatory mediators and enzymes, and the suppression of NF-κB pathway. Moreover, COS stimulate the proliferation of lymphocytes and radical scavenging activity and decrease ROS and reduce MDA in oxidative damaged cells. COS have been shown to increase intracellular antioxidant enzymes, prevent oxidative DNA damage, and inhibit or suppress superoxide anion and NO production. Interestingly, the bioactivity of COS is highly dependent on its physicochemical properties, which may result in new findings and bioactive compounds according to extraction and purification method and/or molecular weights. Therefore, optimization and controllable methods of extraction and polymer synthesis will contribute to reproduce relevant therapeutic effects. For example, decrease in COS MWt is related to their high antioxidative effects. Similarly, increases in DD and positive charges are related to their high anti-inflammatory as well as antioxidative activities. Chemical modifications of COS present a chance for enhancing different biological activities of COS. Future research should be directed towards the understanding of mechanism of action of standardized and chemically characterized COS. All together experimental data and processing technology provide an evidence of defensive potential of COS against glucose-mediated oxidative complications through being in vivo antioxidant, anti-inflammatory, and antidiabetic agents; COS can also regulate many signaling pathways involved in glucose metabolism and homeostasis. The safe profile of COS, diverse mechanism, and MWt-dependent bioactivity lead us to expect a wide range of applications for COS technological formulations.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Acknowledgments

This research was made possible as part of Ministry of Agriculture Malaysia initiative under the New Key Economic Areas Entry Point Project on High Value Herbals awarded to Natural Wellness Biotech (M) Sdn Bhd. The authors express their gratitude and appreciation for the trust and opportunity given.

References

V. K. Mourya, N. N. Inamdar, and Y. M. Choudhari, “Chitooligosaccharides: synthesis, characterization and applications,” Polymer Science Series A, vol. 53, no. 7, pp. 583–612, 2011.
View at: Publisher Site | Google Scholar
B. B. Aam, E. B. Heggset, A. L. Norberg, M. Sørlie, K. M. Vårum, and V. G. H. Eijsink, “Production of chitooligosaccharides and their potential applications in medicine,” Marine Drugs, vol. 8, no. 5, pp. 1482–1517, 2010.
View at: Publisher Site | Google Scholar
C. Muanprasat, P. Wongkrasant, S. Satitsri et al., “Activation of AMPK by chitosan oligosaccharide in intestinal epithelial cells: mechanism of action and potential applications in intestinal disorders,” Biochemical Pharmacology, vol. 96, no. 3, pp. 225–236, 2015.
View at: Publisher Site | Google Scholar
P. Zou, X. Yang, J. Wang et al., “Advances in characterisation and biological activities of chitosan and chitosan oligosaccharides,” Food Chemistry, vol. 190, pp. 1174–1181, 2016.
View at: Publisher Site | Google Scholar
G. Lodhi, Y.-S. Kim, J.-W. Hwang et al., “Chitooligosaccharide and its derivatives: preparation and biological applications,” BioMed Research International, vol. 2014, Article ID 654913, 13 pages, 2014.
View at: Publisher Site | Google Scholar
S. Kim and N. Rajapakse, “Enzymatic production and biological activities of chitosan oligosaccharides (COS): a review,” Carbohydrate Polymers, vol. 62, no. 4, pp. 357–368, 2005.
View at: Publisher Site | Google Scholar
N. M. Alves and J. F. Mano, “Chitosan derivatives obtained by chemical modifications for biomedical and environmental applications,” International Journal of Biological Macromolecules, vol. 43, no. 5, pp. 401–414, 2008.
View at: Publisher Site | Google Scholar
J.-Y. Je, P.-J. Park, and S.-K. Kim, “Free radical scavenging properties of hetero-chitooligosaccharides using an ESR spectroscopy,” Food and Chemical Toxicology, vol. 42, no. 3, pp. 381–387, 2004.
View at: Publisher Site | Google Scholar
S. N. Hamer, S. Cord-Landwehr, X. Biarnés et al., “Enzymatic production of defined chitosan oligomers with a specific pattern of acetylation using a combination of chitin oligosaccharide deacetylases,” Scientific Reports, vol. 5, no. 1, p. 8716, 2015.
View at: Publisher Site | Google Scholar
P. Eaton, J. C. Fernandes, E. Pereira, M. E. Pintado, and F. Xavier Malcata, “Atomic force microscopy study of the antibacterial effects of chitosans on Escherichia coli and Staphylococcus aureus,” Ultramicroscopy, vol. 108, no. 10, pp. 1128–1134, 2008.
View at: Publisher Site | Google Scholar
P.-J. Park, J.-Y. Je, and S.-K. Kim, “Free radical scavenging activity of chitooligosaccharides by electron spin resonance spectrometry,” Journal of Agricultural and Food Chemistry, vol. 51, no. 16, pp. 4624–4627, 2003.
View at: Publisher Site | Google Scholar
R. Huang, E. Mendis, and S.-K. Kim, “Factors affecting the free radical scavenging behavior of chitosan sulfate,” International Journal of Biological Macromolecules, vol. 36, no. 1-2, pp. 120–127, 2005.
View at: Publisher Site | Google Scholar
Y. Yang, R. Shu, J. Shao, G. Xu, and X. Gu, “Radical scavenging activity of chitooligosaccharide with different molecular weights,” European Food Research and Technology, vol. 222, no. 1-2, pp. 36–40, 2006.
View at: Publisher Site | Google Scholar
E. Mendis, M.-M. Kim, N. Rajapakse, and S.-K. Kim, “An in vitro cellular analysis of the radical scavenging efficacy of chitooligosaccharides,” Life Sciences, vol. 80, no. 23, pp. 2118–2127, 2007.
View at: Publisher Site | Google Scholar
S. J. Lee, E. K. Kim, J. W. Hwang, H. J. Oh, P. J. Park, and C. G. Kim, “Antioxidative effects of sulfated chitooligosaccharides on oxidative injury,” Journal of Chitin and Chitosan, vol. 14, no. 4, pp. 192–196, 2009.
View at: Google Scholar
J. C. Fernandes, P. Eaton, H. Nascimento et al., “Antioxidant activity of chitooligosaccharides upon two biological systems: erythrocytes and bacteriophages,” Carbohydrate Polymers, vol. 79, no. 4, pp. 1101–1106, 2010.
View at: Publisher Site | Google Scholar
D.-H. Ngo, Z.-J. Qian, D.-N. Ngo, T.-S. Vo, I. Wijesekara, and S.-K. Kim, “Gallyl chitooligosaccharides inhibit intracellular free radical-mediated oxidation,” Food Chemistry, vol. 128, no. 4, pp. 974–981, 2011.
View at: Publisher Site | Google Scholar
X. Lu, H. Guo, and Y. Zhang, “Protective effects of sulfated chitooligosaccharides against hydrogen peroxide-induced damage in MIN6 cells,” International Journal of Biological Macromolecules, vol. 50, no. 1, pp. 50–58, 2012.
View at: Publisher Site | Google Scholar
S.-K. Chen, C.-H. Hsu, M.-L. Tsai, R.-H. Chen, and G. Drummen, “Inhibition of oxidative stress by low-molecular-weight polysaccharides with various functional groups in skin fibroblasts,” International Journal of Molecular Sciences, vol. 14, no. 10, pp. 19399–19415, 2013.
View at: Publisher Site | Google Scholar
T. Laokuldilok, T. Potivas, N. Kanha et al., “Physicochemical, antioxidant, and antimicrobial properties of chitooligosaccharides produced using three different enzyme treatments,” Food Bioscience, vol. 18, pp. 28–33, 2017.
View at: Publisher Site | Google Scholar
T.-S. Vo, D.-H. Ngo, Q. V. Ta, I. Wijesekara, C.-S. Kong, and S.-K. Kim, “Protective effect of chitin oligosaccharides against lipopolysaccharide-induced inflammatory response in BV-2 microglia,” Cellular Immunology, vol. 277, no. 1-2, pp. 14–21, 2012.
View at: Publisher Site | Google Scholar
X. Dai, P. Chang, Q. Zhu et al., “Chitosan oligosaccharides protect rat primary hippocampal neurons from oligomeric β-amyloid 1-42-induced neurotoxicity,” Neuroscience Letters, vol. 554, pp. 64–69, 2013.
View at: Publisher Site | Google Scholar
C. Hao, L. Gao, Y. Zhang et al., “Acetylated chitosan oligosaccharides act as antagonists against glutamate-induced PC12 cell death via Bcl-2/Bax signal pathway,” Marine Drugs, vol. 13, no. 3, pp. 1267–1289, 2015.
View at: Publisher Site | Google Scholar
K. Li, R. Xing, S. Liu et al., “Separation of chito-oligomers with several degrees of polymerization and study of their antioxidant activity,” Carbohydrate Polymers, vol. 88, no. 3, pp. 896–903, 2012.
View at: Publisher Site | Google Scholar
Z. Luo, X. Dong, Q. Ke, Q. Duan, and L. Shen, “Chitooligosaccharides inhibit ethanol-induced oxidative stress via activation of Nrf2 and reduction of MAPK phosphorylation,” Oncology Reports, vol. 32, no. 5, pp. 2215–2222, 2014.
View at: Publisher Site | Google Scholar
P. Manivasagan, S. Bharathiraja, N. Q. Bui, I. G. Lim, and J. Oh, “Paclitaxel-loaded chitosan oligosaccharide-stabilized gold nanoparticles as novel agents for drug delivery and photoacoustic imaging of cancer cells,” International Journal of Pharmaceutics, vol. 511, no. 1, pp. 367–379, 2016.
View at: Publisher Site | Google Scholar
D.-N. Ngo, M.-M. Kim, and S.-K. Kim, “Chitin oligosaccharides inhibit oxidative stress in live cells,” Carbohydrate Polymers, vol. 74, no. 2, pp. 228–234, 2008.
View at: Publisher Site | Google Scholar
D.-N. Ngo, S.-H. Lee, M.-M. Kim, and S.-K. Kim, “Production of chitin oligosaccharides with different molecular weights and their antioxidant effect in RAW 264.7 cells,” Journal of Functional Foods, vol. 1, no. 2, pp. 188–198, 2009.
View at: Publisher Site | Google Scholar
D.-H. Ngo, Z.-J. Qian, T.-S. Vo, B. Ryu, D.-N. Ngo, and S.-K. Kim, “Antioxidant activity of gallate-chitooligosaccharides in mouse macrophage RAW264.7 cells,” Carbohydrate Polymers, vol. 84, no. 4, pp. 1282–1288, 2011.
View at: Publisher Site | Google Scholar
T. Nidheesh, C. Salim, P. S. Rajini, and P. V. Suresh, “Antioxidant and neuroprotective potential of chitooligomers in Caenorhabditis elegans exposed to monocrotophos,” Carbohydrate Polymers, vol. 135, pp. 138–144, 2016.
View at: Publisher Site | Google Scholar
S.-H. Oh, T.-S. Vo, D.-H. Ngo, S.-Y. Kim, D.-N. Ngo, and S.-K. Kim, “Prevention of H₂O₂-induced oxidative stress in murine microglial BV-2 cells by chitin-oligomers,” Process Biochemistry, vol. 51, no. 12, pp. 2170–2175, 2016.
View at: Publisher Site | Google Scholar
N. Salgaonkar, D. Prakash, N. N. Nawani, and B. P. Kapadnis, “Comparative studies on ability of N-acetylated chitooligosaccharides to scavenge reactive oxygen species and protect dna from oxidative damage,” Indian Journal of Biotechnology, vol. 14, pp. 186–192, 2015.
View at: Google Scholar
S. Shukla, A. Jadaun, V. Arora, R. K. Sinha, N. Biyani, and V. K. Jain, “In vitro toxicity assessment of chitosan oligosaccharide coated iron oxide nanoparticles,” Toxicology Reports, vol. 2, pp. 27–39, 2015.
View at: Publisher Site | Google Scholar
T. Sun, Q. Yao, D. Zhou, and F. Mao, “Antioxidant activity of N-carboxymethyl chitosan oligosaccharides,” Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 21, pp. 5774–5776, 2008.
View at: Publisher Site | Google Scholar
P. Wei, P. Ma, Q.-S. Xu et al., “Chitosan oligosaccharides suppress production of nitric oxide in lipopolysaccharide-induced N9 murine microglial cells in vitro,” Glycoconjugate Journal, vol. 29, no. 5-6, pp. 285–295, 2012.
View at: Publisher Site | Google Scholar
H.-T. Yao, M.-N. Luo, and C.-C. Li, “Chitosan oligosaccharides reduce acetaminophen-induced hepatotoxicity by suppressing CYP-mediated bioactivation,” Journal of Functional Foods, vol. 12, pp. 262–270, 2015.
View at: Publisher Site | Google Scholar
C.-M. Zhang, S.-H. Yu, L.-S. Zhang, Z.-Y. Zhao, and L.-L. Dong, “Effects of several acetylated chitooligosaccharides on antioxidation, antiglycation and NO generation in erythrocyte,” Bioorganic and Medicinal Chemistry Letters, vol. 24, no. 16, pp. 4053–4057, 2014.
View at: Publisher Site | Google Scholar
M. D. L. Trinh, D.-H. Ngo, D.-K. Tran et al., “Prevention of H₂O₂-induced oxidative stress in Chang liver cells by 4-hydroxybenzyl-chitooligomers,” Carbohydrate Polymers, vol. 103, pp. 502–509, 2014.
View at: Publisher Site | Google Scholar
D. Qu and J. Han, “Investigation of the antioxidant activity of chitooligosaccharides on mice with high-fat diet,” Revista Brasileira de Zootecnia, vol. 45, no. 11, pp. 661–666, 2016.
View at: Publisher Site | Google Scholar
C. Xie, X. Wu, C. Long et al., “Chitosan oligosaccharide affects antioxidant defense capacity and placental amino acids transport of sows,” BMC Veterinary Research, vol. 12, no. 1, p. 243, 2016.
View at: Publisher Site | Google Scholar
Z. Jiang, G. Liu, Y. Yang et al., “N-Acetyl chitooligosaccharides attenuate amyloid β-induced damage in animal and cell models of Alzheimer’s disease,” Process Biochemistry, vol. 84, pp. 161–171, 2019.
View at: Publisher Site | Google Scholar
C. Yu, “Chitosan oligosaccharide inhibits LPS-induced apoptosis of vascular endothelial cells through the BKCa channel and the p38 signaling pathway,” International Journal of Molecular Medicine, vol. 30, no. 1, pp. 157–164, 2012.
View at: Publisher Site | Google Scholar
J. Dou, Q. Xu, C. Tan et al., “Effects of chitosan oligosaccharides on neutrophils from glycogen-induced peritonitis mice model,” Carbohydrate Polymers, vol. 75, no. 1, pp. 119–124, 2009.
View at: Publisher Site | Google Scholar
I.-M. Fang, C.-M. Yang, and C.-H. Yang, “Chitosan oligosaccharides prevented retinal ischemia and reperfusion injury via reduced oxidative stress and inflammation in rats,” Experimental Eye Research, vol. 130, pp. 38–50, 2015.
View at: Publisher Site | Google Scholar
S. Jia, Z. Lu, Z. Gao et al., “Chitosan oligosaccharides alleviate cognitive deficits in an amyloid-β1-42-induced rat model of Alzheimer’s disease,” International Journal of Biological Macromolecules, vol. 83, pp. 416–425, 2016.
View at: Publisher Site | Google Scholar
J. Niu, H.-Z. Lin, S.-G. Jiang et al., “Comparison of effect of chitin, chitosan, chitosan oligosaccharide and N-acetyl-d-glucosamine on growth performance, antioxidant defenses and oxidative stress status of Penaeus monodon,” Aquaculture, vol. 372–375, pp. 1–8, 2013.
View at: Publisher Site | Google Scholar
Y. Qu, J. Xu, H. Zhou, R. Dong, M. Kang, and J. Zhao, “Chitin oligosaccharide (COS) reduces antibiotics dose and prevents antibiotics-caused side effects in adolescent idiopathic scoliosis (AIS) patients with spinal fusion surgery,” Marine Drugs, vol. 15, no. 3, p. 70, 2017.
View at: Publisher Site | Google Scholar
J. Wan, F. Jiang, Q. Xu et al., “New insights into the role of chitosan oligosaccharide in enhancing growth performance, antioxidant capacity, immunity and intestinal development of weaned pigs,” RSC Advances, vol. 7, no. 16, pp. 9669–9679, 2017.
View at: Publisher Site | Google Scholar
S.-L. Wang, J.-Y. Liou, T.-W. Liang, and K.-C. Liu, “Conversion of squid pen by using Serratia sp. TKU020 fermentation for the production of enzymes, antioxidants, and N-acetyl chitooligosaccharides,” Process Biochemistry, vol. 44, no. 8, pp. 854–861, 2009.
View at: Publisher Site | Google Scholar
H.-T. Yao, M.-N. Luo, L.-B. Hung et al., “Effects of chitosan oligosaccharides on drug-metabolizing enzymes in rat liver and kidneys,” Food and Chemical Toxicology, vol. 50, no. 5, pp. 1171–1177, 2012.
View at: Publisher Site | Google Scholar
H. J. Yoon, M. E. Moon, H. S. Park et al., “Effects of chitosan oligosaccharide (COS) on the glycerol-induced acute renal failure in vitro and in vivo,” Food and Chemical Toxicology, vol. 46, no. 2, pp. 710–716, 2008.
View at: Publisher Site | Google Scholar
C. Xie, X. Wu, X. Guo et al., “Maternal chitosan oligosaccharide supplementation affecting expression of circadian clock genes, and possible association with hepatic cholesterol accumulation in suckling piglets,” Biological Rhythm Research, vol. 47, no. 2, pp. 253–265, 2015.
View at: Publisher Site | Google Scholar
M. J. Chung, J. K. Park, and Y. I. Park, “Anti-inflammatory effects of low-molecular weight chitosan oligosaccharides in IgE-antigen complex-stimulated RBL-2H3 cells and asthma model mice,” International Immunopharmacology, vol. 12, no. 2, pp. 453–459, 2012.
View at: Publisher Site | Google Scholar
Y. Dang, S. Li, W. Wang et al., “The effects of chitosan oligosaccharide on the activation of murine spleen CD11c+ dendritic cells via Toll-like receptor 4,” Carbohydrate Polymers, vol. 83, no. 3, pp. 1075–1081, 2011.
View at: Publisher Site | Google Scholar
A. Deters, F. Petereit, J. Schmidgall, and A. Hensel, “N-Acetyl-D-glucosamine oligosaccharides induce mucin secretion from colonic tissue and induce differentiation of human keratinocytes,” Journal of Pharmacy and Pharmacology, vol. 60, no. 2, pp. 197–204, 2008.
View at: Publisher Site | Google Scholar
J.-H. Hyung, C.-B. Ahn, B. Il Kim, K. Kim, and J.-Y. Je, “Involvement of Nrf2-mediated heme oxygenase-1 expression in anti-inflammatory action of chitosan oligosaccharides through MAPK activation in murine macrophages,” European Journal of Pharmacology, vol. 793, pp. 43–48, 2016.
View at: Publisher Site | Google Scholar
J.-H. Kim, Y.-S. Kim, J.-W. Hwang et al., “Sulfated chitosan oligosaccharides suppress LPS-induced NO production via JNK and NF-κB inactivation,” Molecules, vol. 19, no. 11, pp. 18232–18247, 2014.
View at: Publisher Site | Google Scholar
W. Kunanusornchai, B. Witoonpanich, T. Tawonsawatruk, R. Pichyangkura, V. Chatsudthipong, and C. Muanprasat, “Chitosan oligosaccharide suppresses synovial inflammation via AMPK activation: an in vitro and in vivo study,” Pharmacological Research, vol. 113, pp. 458–467, 2016.
View at: Publisher Site | Google Scholar
X. Li, C. Zhou, X. Chen, J. Wang, and J. Tian, “Effects of five chitosan oligosaccharides on nuclear factor-kappa B signaling pathway,” Journal of Wuhan University of Technology-Mater Sci Ed, vol. 27, no. 2, pp. 276–279, 2012.
View at: Publisher Site | Google Scholar
Y. Li, H. Liu, Q.-S. Xu, Y.-G. Du, and J. Xu, “Chitosan oligosaccharides block LPS-induced O-GlcNAcylation of NF-κB and endothelial inflammatory response,” Carbohydrate Polymers, vol. 99, pp. 568–578, 2014.
View at: Publisher Site | Google Scholar
Y.-S. Lin, M.-F. Wu, Y. Takamori, Y. Okamoto, and S. Minami, “In vivomodulatory effects of chitooligosaccharide nanoparticles on mouse serum cytokines and splenocytes,” Journal of Experimental Nanoscience, vol. 9, no. 8, pp. 860–870, 2013.
View at: Publisher Site | Google Scholar
H.-T. Liu, W.-M. Li, P. Huang et al., “Chitosan oligosaccharides inhibit TNF-α-induced VCAM-1 and ICAM-1 expression in human umbilical vein endothelial cells by blocking p38 and ERK1/2 signaling pathways,” Carbohydrate Polymers, vol. 81, no. 1, pp. 49–56, 2010.
View at: Publisher Site | Google Scholar
Y. Qiao, Y. Ruan, C. Xiong et al., “Chitosan oligosaccharides suppressant LPS binding to TLR4/MD-2 receptor complex,” Carbohydrate Polymers, vol. 82, no. 2, pp. 405–411, 2010.
View at: Publisher Site | Google Scholar
T.-S. Vo, D.-H. Ngo, L. G. Bach, D.-N. Ngo, and S.-K. Kim, “The free radical scavenging and anti-inflammatory activities of gallate-chitooligosaccharides in human lung epithelial A549 cells,” Process Biochemistry, vol. 54, pp. 188–194, 2017.
View at: Publisher Site | Google Scholar
Q. Xu, W. Wang, W. Yang, Y. Du, and L. Song, “Chitosan oligosaccharide inhibits EGF-induced cell growth possibly through blockade of epidermal growth factor receptor/mitogen-activated protein kinase pathway,” International Journal of Biological Macromolecules, vol. 98, pp. 502–505, 2017.
View at: Publisher Site | Google Scholar
Q. Xu, W. Wang, C. Qu et al., “Chitosan oligosaccharides inhibit epithelial cell migration through blockade of N -acetylglucosaminyltransferase V and branched GlcNAc structure,” Carbohydrate Polymers, vol. 170, pp. 241–246, 2017.
View at: Publisher Site | Google Scholar
Y.-L. Yin, Z. R. Tang, Z. H. Sun et al., “Effect of galacto-mannan-oligosaccharides or chitosan supplementation on cytoimmunity and humoral immunity in early-weaned piglets,” Asian-Australasian Journal of Animal Sciences, vol. 21, no. 5, pp. 723–731, 2008.
View at: Publisher Site | Google Scholar
H. J. Yoon, M. E. Moon, H. S. Park, S. Y. Im, and Y. H. Kim, “Chitosan oligosaccharide (COS) inhibits LPS-induced inflammatory effects in RAW 264.7 macrophage cells,” Biochemical and Biophysical Research Communications, vol. 358, no. 3, pp. 954–959, 2007.
View at: Publisher Site | Google Scholar
M. Yousef, R. Pichyangkura, S. Soodvilai, V. Chatsudthipong, and C. Muanprasat, “Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action,” Pharmacological Research, vol. 66, no. 1, pp. 66–79, 2012.
View at: Publisher Site | Google Scholar
P. Zhang, W. Liu, Y. Peng, B. Han, and Y. Yang, “Toll like receptor 4 (TLR4) mediates the stimulating activities of chitosan oligosaccharide on macrophages,” International Immunopharmacology, vol. 23, no. 1, pp. 254–261, 2014.
View at: Publisher Site | Google Scholar
C. Zhang, L. Yu, Y. Zhou, Q. Zhao, and S.-Q. Liu, “Chitosan oligosaccharides inhibit IL-1β-induced chondrocyte apoptosis via the P38 MAPK signaling pathway,” Glycoconjugate Journal, vol. 33, no. 5, pp. 735–744, 2016.
View at: Publisher Site | Google Scholar
Y. Yang, R. Xing, S. Liu et al., “Immunostimulatory effects of Chitooligosaccharides on RAW 264.7 mouse macrophages via regulation of the MAPK and PI3K/Akt signaling pathways,” Marine Drugs, vol. 17, no. 1, p. 36, 2019.
View at: Publisher Site | Google Scholar
P. Santos-Moriano, L. Fernandez-Arrojo, M. Mengibar et al., “Enzymatic production of fully deacetylated chitooligosaccharides and their neuroprotective and anti-inflammatory properties,” Biocatalysis and Biotransformation, vol. 36, no. 1, pp. 57–67, 2018.
View at: Publisher Site | Google Scholar
R. Huang, N. Rajapakse, and S.-K. Kim, “Structural factors affecting radical scavenging activity of chitooligosaccharides (COS) and its derivatives,” Carbohydrate Polymers, vol. 63, no. 1, pp. 122–129, 2006.
View at: Publisher Site | Google Scholar
E. H. Choi, H. P. Yang, and H. S. Chun, “Chitooligosaccharide ameliorates diet-induced obesity in mice and affects adipose gene expression involved in adipogenesis and inflammation,” Nutrition Research, vol. 32, no. 3, pp. 218–228, 2012.
View at: Publisher Site | Google Scholar
Y. Qiao, X.-F. Bai, and Y.-G. Du, “Chitosan oligosaccharides protect mice from LPS challenge by attenuation of inflammation and oxidative stress,” International Immunopharmacology, vol. 11, no. 1, pp. 121–127, 2011.
View at: Publisher Site | Google Scholar
R. Pangestuti, S.-S. Bak, and S.-K. Kim, “Attenuation of pro-inflammatory mediators in LPS-stimulated BV2 microglia by chitooligosaccharides via the MAPK signaling pathway,” International Journal of Biological Macromolecules, vol. 49, no. 4, pp. 599–606, 2011.
View at: Publisher Site | Google Scholar
H.-T. Liu, P. Huang, P. Ma, Q.-S. Liu, C. Yu, and Y.-G. Du, “Chitosan oligosaccharides suppress LPS-induced IL-8 expression in human umbilical vein endothelial cells through blockade of p38 and Akt protein kinases,” Acta Pharmacologica Sinica, vol. 32, no. 4, pp. 478–486, 2011.
View at: Publisher Site | Google Scholar
H. E. Moon, M. N. Islam, B. R. Ahn et al., “Protein tyrosine phosphatase 1B and α-glucosidase inhibitory phlorotannins from edible Brown Algae, Ecklonia stoloniferaandEisenia bicyclis,” Bioscience, Biotechnology, and Biochemistry, vol. 75, no. 8, pp. 1472–1480, 2011.
View at: Publisher Site | Google Scholar
C. Qin, Y. Zhang, W. Liu, L. Xu, Y. Yang, and Z. Zhou, “Effects of chito-oligosaccharides supplementation on growth performance, intestinal cytokine expression, autochthonous gut bacteria and disease resistance in hybrid tilapia Oreochromis niloticus ♀ × Oreochromis aureus ♂,” Fish and Shellfish Immunology, vol. 40, no. 1, pp. 267–274, 2014.
View at: Publisher Site | Google Scholar
J. W. Yang, G. Tian, D. W. Chen et al., “Involvement of PKA signalling in anti-inflammatory effects of chitosan oligosaccharides in IPEC-J2 porcine epithelial cells,” Journal of Animal Physiology and Animal Nutrition, vol. 102, no. 1, pp. 252–259, 2017.
View at: Publisher Site | Google Scholar
B. Liu, W.-S. Liu, B.-Q. Han, and Y.-Y. Sun, “Antidiabetic effects of chitooligosaccharides on pancreatic islet cells in streptozotocin-induced diabetic rats,” World Journal of Gastroenterology, vol. 13, no. 5, p. 725, 2007.
View at: Publisher Site | Google Scholar
C. Ju, W. Yue, Z. Yang et al., “Antidiabetic effect and mechanism of chitooligosaccharides,” Biological and Pharmaceutical Bulletin, vol. 33, no. 9, pp. 1511–1516, 2010.
View at: Publisher Site | Google Scholar
Y. Lee, H. Hirose, M. Ohneda, J. H. Johnson, J. D. McGarry, and R. H. Unger, “Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships,” Proceedings of the National Academy of Sciences, vol. 91, no. 23, pp. 10878–10882, 1994.
View at: Publisher Site | Google Scholar
V. Poitout and R. P. Robertson, “Minireview: secondary β-cell failure in type 2 diabetes-A convergence of glucotoxicity and lipotoxicity,” Endocrinology, vol. 143, no. 2, pp. 339–342, 2002.
View at: Publisher Site | Google Scholar
M. Y. Donath, J. Størling, K. Maedler, and T. Mandrup-Poulsen, “Inflammatory mediators and islet?-cell failure: a link between type 1 and type 2 diabetes,” Journal of Molecular Medicine, vol. 81, no. 8, pp. 455–470, 2003.
View at: Publisher Site | Google Scholar
J. L. Leahy, S. Bonner-Weir, and G. C. Weir, “β-Cell dysfunction induced by chronic hyperglycemia: current ideas on mechanism of impaired glucose-induced insulin secretion,” Diabetes Care, vol. 15, no. 3, pp. 442–455, 1992.
View at: Publisher Site | Google Scholar
H. Yki-järvinen, “Glucose toxicity,” Endocrine Reviews, vol. 13, no. 3, pp. 415–431, 1992.
View at: Publisher Site | Google Scholar
G. C. Weir, D. R. Laybutt, H. Kaneto, S. Bonner-Weir, and A. Sharma, “Beta-cell adaptation and decompensation during the progression of diabetes,” Diabetes, vol. 50, no. 1, pp. S154–S159, 2001.
View at: Publisher Site | Google Scholar
D. Fukudome, M. Matsuda, T. Kawasaki, Y. Ago, and T. Matsuda, “The radical scavenger edaravone counteracts diabetes in multiple low-dose streptozotocin-treated mice,” European Journal of Pharmacology, vol. 583, no. 1, pp. 164–169, 2008.
View at: Publisher Site | Google Scholar
N. Takasu, I. Komiya, T. Asawa, Y. Nagasawa, and T. Yamada, “Streptozocin- and alloxan-induced H₂O₂ generation and DNA fragmentation in pancreatic islets. H₂O₂ as mediator for DNA fragmentation,” Diabetes, vol. 40, no. 9, pp. 1141–1145, 1991.
View at: Publisher Site | Google Scholar
W.-P. Yuan, B. Liu, C.-H. Liu et al., “Antioxidant activity of chito-oligosaccharides on pancreatic islet cells in streptozotocin-induced diabetes in rats,” World Journal of Gastroenterology, vol. 15, no. 11, p. 1339, 2009.
View at: Publisher Site | Google Scholar
P. Stanely, M. Prince, and V. P. Menon, “Hypoglycaemic and other related actions of Tinospora cordifolia roots in alloxan-induced diabetic rats,” Journal of Ethnopharmacology, vol. 70, no. 1, pp. 9–15, 2000.
View at: Publisher Site | Google Scholar
K. Srinivasan, B. Viswanad, L. Asrat, C. L. Kaul, and P. Ramarao, “Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening,” Pharmacological Research, vol. 52, no. 4, pp. 313–320, 2005.
View at: Publisher Site | Google Scholar
A. Zisman, O. D. Peroni, E. D. Abel et al., “Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance,” Nature Medicine, vol. 6, no. 8, pp. 924–928, 2000.
View at: Publisher Site | Google Scholar
G. I. Shulman, “Cellular mechanisms of insulin resistance,” Journal of Clinical Investigation, vol. 106, no. 2, pp. 171–176, 2000.
View at: Publisher Site | Google Scholar
D. M. Katiyar, B. Singh, A. M. Lall, and C. Haldar, “Evaluation of antidiabetic and hypolipidemic activity of chitooligosaccharides in alloxan-induced diabetes mellitus in mice,” International Journal of Pharma and Bio Sciences, vol. 2, no. 1, pp. 407–416, 2011.
View at: Google Scholar
B. G. Ha, J.-E. Park, and Y. H. Shon, “Stimulatory effect of balanced deep-sea water containing chitosan oligosaccharides on glucose uptake in C2C12 myotubes,” Marine Biotechnology, vol. 18, no. 4, pp. 475–484, 2016.
View at: Publisher Site | Google Scholar
S.-Y. Yu, Y.-I. Kwon, C. Lee, E. Apostolidis, and Y.-C. Kim, “Antidiabetic effect of chitosan oligosaccharide (GO2KA1) is mediated via inhibition of intestinal alpha-glucosidase and glucose transporters and PPARγ expression,” BioFactors, vol. 43, no. 1, pp. 90–99, 2017.
View at: Publisher Site | Google Scholar
J. S. Teodoro, A. P. Gomes, A. T. Varela, F. V. Duarte, A. P. Rolo, and C. M. Palmeira, “Hepatic and skeletal muscle mitochondrial toxicity of chitosan oligosaccharides of normal and diabetic rats,” Toxicology Mechanisms and Methods, vol. 26, no. 9, pp. 650–657, 2016.
View at: Publisher Site | Google Scholar
J. Wang, X. Si, W. Shang, Z. Zhou, P. Strappe, and C. Blanchard, “Effect of single or combined administration of resistant starch and chitosan oligosaccharides on insulin resistance in rats fed with a high-fat diet,” Starch-Stärke, vol. 69, no. 7-8, Article ID 1600209, 2017.
View at: Publisher Site | Google Scholar
X. Wu, J. Wang, Y. Shi et al., “N-Acetyl-chitobiose ameliorates metabolism dysfunction through Erk/p38 MAPK and histone H3 phosphorylation in type 2 diabetes mice,” Journal of Functional Foods, vol. 28, pp. 96–105, 2017.
View at: Publisher Site | Google Scholar
B. Bahar, J. V. O’Doherty, and T. Sweeney, “A potential role of IL-6 in the chito-oligosaccharide-mediated inhibition of adipogenesis,” British Journal of Nutrition, vol. 106, no. 8, pp. 1142–1153, 2011.
View at: Publisher Site | Google Scholar
E. J. Cho, A. Rahman, S. W. Kim et al., “Chitosan oligosaccharides inhibit adipogenesis in 3T3-L1 adipocytes,” Journal of Microbiology and Biotechnology, vol. 18, no. 1, pp. 80–87, 2008.
View at: Google Scholar
M. A. Rahman, S. G. Kumar, S. W. Kim et al., “Proteomic analysis for inhibitory effect of chitosan oligosaccharides on 3T3-L1 adipocyte differentiation,” Proteomics, vol. 8, no. 3, pp. 569–581, 2008.
View at: Publisher Site | Google Scholar
B. Huang, D. Xiao, B. Tan et al., “Chitosan oligosaccharide reduces intestinal inflammation that involves calcium-sensing receptor (CaSR) activation in lipopolysaccharide (LPS)-Challenged piglets,” Journal of Agricultural and Food Chemistry, vol. 64, no. 1, pp. 245–252, 2015.
View at: Publisher Site | Google Scholar
S.-H. Jo, K.-S. Ha, K.-S. Moon et al., “Molecular weight dependent glucose lowering effect of low molecular weight chitosan oligosaccharide (GO2KA1) on postprandial blood glucose level in SD rats model,” International Journal of Molecular Sciences, vol. 14, no. 7, pp. 14214–14224, 2013.
View at: Publisher Site | Google Scholar
N.-H. Kang, W. K. Lee, B.-R. Yi et al., “Risk of cardiovascular disease is suppressed by dietary supplementation with protamine and chitooligosaccharide in Sprague-Dawley rats,” Molecular Medicine Reports, vol. 7, no. 1, pp. 127–133, 2012.
View at: Publisher Site | Google Scholar
D. Katiyar, B. Singh, A. M. Lall, and C. Haldar, “Efficacy of chitooligosaccharides for the management of diabetes in alloxan induced mice: a correlative study with antihyperlipidemic and antioxidative activity,” European Journal of Pharmaceutical Sciences, vol. 44, no. 4, pp. 534–543, 2011.
View at: Publisher Site | Google Scholar
O. Keser, T. Bilal, H. C. Kutay, I. Abas, and H. Eseceli, “Effects of chitosan oligosaccharide and/or beta-glucan supplementation to diets containing organic zinc on performance and some blood indices in broilers,” Pakistan Veterinary Journal, vol. 32, no. 1, 2012.
View at: Google Scholar
J.-G. Kim, S.-H. Jo, K.-S. Ha et al., “Effect of long-term supplementation of low molecular weight chitosan oligosaccharide (GO2KA1) on fasting blood glucose and HbA1c in db/db mice model and elucidation of mechanism of action,” BMC Complementary and Alternative Medicine, vol. 14, no. 1, 2014.
View at: Publisher Site | Google Scholar
J. N. Kim, I. Y. Chang, H. I. Kim, and S. P. Yoon, “Long-term effects of chitosan oligosaccharide in streptozotocin-induced diabetic rats,” Islets, vol. 1, no. 2, pp. 111–116, 2009.
View at: Publisher Site | Google Scholar
S. G. Kumar, M. A. Rahman, S. H. Lee, H. S. Hwang, H. A. Kim, and J. W. Yun, “Plasma proteome analysis for anti-obesity and anti-diabetic potentials of chitosan oligosaccharides in ob/ob mice,” Proteomics, vol. 9, no. 8, pp. 2149–2162, 2009.
View at: Publisher Site | Google Scholar
M. A. Rahman, S. G. Kumar, and J. W. Yun, “Proteome analysis in adipose tissue of ob/ob mice in response to chitosan oligosaccharides treatment,” Biotechnology and Bioprocess Engineering, vol. 15, no. 4, pp. 559–571, 2010.
View at: Publisher Site | Google Scholar
D. Wang, J. Han, Y. Yu et al., “Chitosan oligosaccharide decreases very-low-density lipoprotein triglyceride and increases high-density lipoprotein cholesterol in high-fat-diet-fed rats,” Experimental Biology and Medicine, vol. 236, no. 9, pp. 1064–1069, 2011.
View at: Publisher Site | Google Scholar
C. Xie, X. Guo, C. Long et al., “Supplementation of the sow diet with chitosan oligosaccharide during late gestation and lactation affects hepatic gluconeogenesis of suckling piglets,” Animal Reproduction Science, vol. 159, pp. 109–117, 2015.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2019 Ilias Marmouzi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

1659

Downloads

1426

Citations